AbbVie, Janssen, Novartis, Pfizer and UCB to jointly advance 'digital' endpoint for atopic dermatitis

As the competition around the lucrative atopic dermatitis space heats up, AbbVie, Janssen, Novartis, Pfizer, and UCB are coming together in a pre-competitive collaboration to advance nocturnal scratch as a “digital” endpoint for the skin condition.